$3.40
1.80% yesterday
NYSE, Sep 04, 10:18 pm CET
ISIN
US74168J1016
Symbol
PRME

Prime Medicine Target price 2025 - Analyst rating & recommendation

Prime Medicine Classifications & Recommendation:

Buy
72%
Hold
28%

Prime Medicine Price Target

Target Price $7.14
Price $3.40
Potential
Number of Estimates 8
8 Analysts have issued a price target Prime Medicine 2026 . The average Prime Medicine target price is $7.14. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 13 Analysts recommend Prime Medicine to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Prime Medicine stock has an average upside potential 2026 of . Most analysts recommend the Prime Medicine stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 2.98 8.34
179.87%
EBITDA Margin -6,588.59% -2,067.29%
68.62%
Net Margin -6,573.15% -1,965.22%
70.10%

13 Analysts have issued a sales forecast Prime Medicine 2025 . The average Prime Medicine sales estimate is

$8.3m
Unlock
. This is
68.15% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$37.9m 664.54%
Unlock
, the lowest is
$2.5m 49.23%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $3.0m
2025
$8.3m 179.87%
Unlock
2026
$3.0m 64.06%
Unlock
2027
$20.1m 570.34%
Unlock
2028
$1.5m 92.55%
Unlock
2029
$6.0m 299.53%
Unlock
2030
$19.7m 229.96%
Unlock
2031
$149m 656.31%
Unlock
2032
$520m 248.93%
Unlock

6 Analysts have issued an Prime Medicine EBITDA forecast 2025. The average Prime Medicine EBITDA estimate is

$-172m
Unlock
. This is
12.65% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-153m 22.60%
Unlock
, the lowest is
$-184m 6.53%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-196m 1.90%
2025
$-172m 12.19%
Unlock
2026
$-148m 14.41%
Unlock
2027
$-163m 10.19%
Unlock

EBITDA Margin

2024 -6,588.59%
2025
-2,067.29% 68.62%
Unlock
2026
-4,924.03% 138.19%
Unlock
2027
-809.44% 83.56%
Unlock

13 Prime Medicine Analysts have issued a net profit forecast 2025. The average Prime Medicine net profit estimate is

$-164m
Unlock
. This is
17.75% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-150m 24.88%
Unlock
, the lowest is
$-191m 4.10%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-196m 1.14%
2025
$-164m 16.33%
Unlock
2026
$-127m 22.76%
Unlock
2027
$-121m 4.36%
Unlock
2028
$-112m 7.77%
Unlock
2029
$-102m 8.78%
Unlock
2030
$-91.2m 10.45%
Unlock
2031
$-44.4m 51.38%
Unlock
2032
$96.0m 316.53%
Unlock

Net Margin

2024 -6,573.15%
2025
-1,965.22% 70.10%
Unlock
2026
-4,223.78% 114.93%
Unlock
2027
-602.64% 85.73%
Unlock
2028
-7,464.19% 1,138.58%
Unlock
2029
-1,704.13% 77.17%
Unlock
2030
-462.55% 72.86%
Unlock
2031
-29.73% 93.57%
Unlock
2032
18.45% 162.06%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.65 -1.22
24.31% 26.06%
P/E negative
EV/Sales 59.16

13 Analysts have issued a Prime Medicine forecast for earnings per share. The average Prime Medicine EPS is

$-1.22
Unlock
. This is
20.78% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.11 27.92%
Unlock
, the lowest is
$-1.42 7.79%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.65 24.31%
2025
$-1.22 26.06%
Unlock
2026
$-0.94 22.95%
Unlock
2027
$-0.90 4.26%
Unlock
2028
$-0.83 7.78%
Unlock
2029
$-0.76 8.43%
Unlock
2030
$-0.68 10.53%
Unlock
2031
$-0.33 51.47%
Unlock
2032
$0.71 315.15%
Unlock

P/E ratio

Current -2.17 7.77%
2025
-2.74 26.34%
Unlock
2026
-3.55 29.56%
Unlock
2027
-3.71 4.51%
Unlock
2028
-4.02 8.36%
Unlock
2029
-4.41 9.70%
Unlock
2030
-4.92 11.56%
Unlock
2031
-10.13 105.89%
Unlock
2032
4.68 146.20%
Unlock

Based on analysts' sales estimates for 2025, the Prime Medicine stock is valued at an EV/Sales of

59.16
Unlock
and an P/S ratio of
71.36
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 99.48 83.27%
2025
59.16 40.53%
Unlock
2026
164.64 178.28%
Unlock
2027
24.56 85.08%
Unlock
2028
329.83 1,242.91%
Unlock
2029
82.55 74.97%
Unlock
2030
25.02 69.69%
Unlock
2031
3.31 86.78%
Unlock
2032
0.95 71.34%
Unlock

P/S ratio

Current 119.99 86.22%
2025
71.36 40.53%
Unlock
2026
198.59 178.28%
Unlock
2027
29.63 85.08%
Unlock
2028
397.84 1,242.91%
Unlock
2029
99.58 74.97%
Unlock
2030
30.18 69.69%
Unlock
2031
3.99 86.78%
Unlock
2032
1.14 71.34%
Unlock

Current Prime Medicine Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Chardan Capital
Locked
Locked
Locked Aug 08 2025
Citigroup
Locked
Locked
Locked May 27 2025
JP Morgan
Locked
Locked
Locked May 20 2025
HC Wainwright & Co.
Locked
Locked
Locked May 20 2025
JMP Securities
Locked
Locked
Locked May 20 2025
Chardan Capital
Locked
Locked
Locked May 19 2025
Chardan Capital
Locked
Locked
Locked Mar 20 2025
Analyst Rating Date
Locked
Chardan Capital:
Locked
Locked
Aug 08 2025
Locked
Citigroup:
Locked
Locked
May 27 2025
Locked
JP Morgan:
Locked
Locked
May 20 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 20 2025
Locked
JMP Securities:
Locked
Locked
May 20 2025
Locked
Chardan Capital:
Locked
Locked
May 19 2025
Locked
Chardan Capital:
Locked
Locked
Mar 20 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today